Host: John E. Anderson, MD Host: John Buse, MD, PhD Host: Carol Wysham, MD The wintertime presents new challenges for patients with chronic diseases, specifically diabetes. But with the spread of COVID-19, how can we help keep our patients safe all winter long? Tune in to hear our Diabetes Discourse hosts Drs. Carol Wysham, John Buse, and John Anderson discuss strategies to effectively manage patients with diabetes during these winter months. Published December X, 2020

Host: Linda Bernstein, Pharm.D. On this episode of The Drug Report, pharmacist Dr. Linda Bernstein focuses on a recent CVS Health announcement of their new plan that allows employers and health plan sponsors to work within a formulary and plan design to offer all types of diabetes medications—including insulin—at zero-dollar out of pocket for their members without raising costs for the plan sponsor or increasing premiums or deductibles for all plan members.

Host: Linda Bernstein, Pharm.D. In this episode of The Drug Report, pharmacist Dr. Linda Bernstein highlights some diabetes medications that have achieved or are pending approval for new indications pertaining to cardiovascular disease risk reduction.

Host: Barnett Mennen, MD Guest: Sarah Hallberg, MD Carbohydrates are our main source of energy and provide important nutrients for good health. However, they are also the main culprit behind elevated blood sugar and are problematic for diabetic patients trying to control their blood sugar levels. Host Dr. Barry Mennen sits down with Dr. Sarah Hallberg to talk about carbohydrate restriction as a key to successful weight loss programs. She prescribes that adherence to a low-carb, high-fat diet is vital to patients for controlling their diabetes, with the possibility of being able to come off medications over time. Dr. Sarah Hallberg is the Medical Director at Virta Health and Founder of the Indiana University-Arnett Health Medical Weight Loss Program in Lafayette, Indiana.

Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk. Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs. Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch. A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at [email protected]. Released 5/16/2017

Host: Brian P. McDonough, MD, FAAFP Diabulimia, defined as the manipulation of insulin treatments by Type 1 diabetic patients in order to lose weight, is a rising problem among teens and young adults in the U.S, particularly young women. Joining Dr. Brian McDonough to discuss this dual diagnosis phenomenon of diabetes and eating disorders, ways in which they exacerbate other disease processes, the long term consequences, and management priorities for phycisians is author and registered dietitian Susan Weiner. Susan is a recipient of the AADE Diabetes Educator of the Year award and has devoted much of her writing and clinical expertise to addressing diabulimia in at-risk patients.

[Read the Article] Despite targeted efforts to reduce obesity through diet and exercise, these rates continue to rise. A new study from Ontario, Canada found that obesity and diabetes rates were lower in more walkable neighborhoods compared to less walkable neighborhoods, where they saw an increase in these rates.Researchers from St. Michael's Hospital in Toronto studied almost 9,000 neighborhoods in Southern Ontario looking at walkability scores, along with government health data and survey results during a twelve-year period. They examined whether neighborhoods that were more walkable experienced a slower increase in obesity and diabetes compared to less walkable neighborhoods. [Watch more videos of The JAMA Report]

Host: Jennifer Caudle, DO Host Jennifer Caudel, DO welcomes Jay Shubrook, DO, Director of Clinical Research and Diabetes Services at Touro University-California College of Osteopathic Medicine. Recorded on site at the American Osteopathic Association's annual medical education conference, Dr. Shubrook discusses a pilot study in which newly diagnosed type 2 diabetes patients were treated with early insulin rather than lifestyle changes and oral therapies alone. The results suggested not only good safety profiles, but also better long-term outcomes for patients.

[Read the Article] Proliferative diabetic retinopathy (PDR) is a leading cause of vision loss in patients with diabetes, resulting in up to 24,000 cases of blindness each year in the United States. Laser therapy has been the most common treatment used to help reduce severe vision loss, but the procedure has many side effects including permanent loss of peripheral vision and swelling of the retina.A group of researchers from across the US tested an alternative treatment using an injectable medication called ranibizumab, to see if it would be as effective as the laser therapy. They studied more than 300 patients with PDR, assigning them to either receive standard laser therapy or an injection into the eye. In total, they treated close to 400 eyes.Outcomes, especially loss of vision, were compared at two years. Over the two year period, researchers found that patients receiving the injections of medication had fewer side effects and did somewhat better in terms of vision loss than those who received laser therapy. [Watch more videos of The JAMA Report]

Host: John J. Russell, MD Guest: Candis Morello, PharmD, CDE Candis M Morello, Professor of Clinical Pharmacy at UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, joins Dr. John Russell to talk about team-based care integrations of certified diabetes educators to help empower diabetes patients and improve long-term outcomes. Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only. Brought to you by